3-(4-((2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-1-(piperazin-1-yl)propan-1-one

ID: ALA4212656

PubChem CID: 68379165

Max Phase: Preclinical

Molecular Formula: C24H31N5O

Molecular Weight: 405.55

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  CCc1nn2c(C)cc(C)nc2c1Cc1ccc(CCC(=O)N2CCNCC2)cc1

Standard InChI:  InChI=1S/C24H31N5O/c1-4-22-21(24-26-17(2)15-18(3)29(24)27-22)16-20-7-5-19(6-8-20)9-10-23(30)28-13-11-25-12-14-28/h5-8,15,25H,4,9-14,16H2,1-3H3

Standard InChI Key:  NACVEUIUKZPVQS-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 30 33  0  0  0  0  0  0  0  0999 V2000
    7.4159  -11.2409    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.8570  -11.9294    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6754  -11.8917    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0508  -11.1597    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.7934  -10.5135    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.6048  -10.4706    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8149   -9.6856    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.1331   -9.2433    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5019   -9.7550    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.0900   -8.4272    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7752   -7.9818    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5996  -11.2781    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1174  -12.5791    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.2341   -9.6824    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.2330  -10.5020    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.9410  -10.9109    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.6507  -10.5015    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.6478   -9.6788    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.9392   -9.2736    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.5263   -9.2740    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.3590  -10.9090    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.0661  -10.4993    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.7744  -10.9068    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.4815  -10.4971    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   15.1865  -10.9089    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.8915  -10.5027    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.8944   -9.6851    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   15.1862   -9.2755    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.4751   -9.6834    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.7757  -11.7240    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  5  1  1  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  6  1  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9  5  1  0
  8 10  1  0
 10 11  1  0
  1 12  1  0
  3 13  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 14  1  0
 14 20  1  0
 20  7  1  0
 17 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  1  0
 24 29  1  0
 25 26  1  0
 26 27  1  0
 27 28  1  0
 28 29  1  0
 23 30  2  0
M  END

Alternative Forms

1. Parent:

   

   ALA4212656

   3-[4-[(2-Ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl]phenyl]-1-piperazin-1-ylpropan-1-one

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 405.55

Molecular Weight (Monoisotopic): 405.2529

AlogP: 2.86

#Rotatable Bonds: 6

Polar Surface Area: 62.53

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 7.82

CX LogP: 3.09

CX LogD: 2.53

Aromatic Rings: 3

Heavy Atoms: 30

QED Weighted: 0.69

Np Likeness Score: -1.24

References

1. Velcicky J, Miltz W, Oberhauser B, Orain D, Vaupel A, Weigand K, Dawson King J, Littlewood-Evans A, Nash M, Feifel R, Loetscher P..  (2017)  Development of Selective, Orally Active GPR4 Antagonists with Modulatory Effects on Nociception, Inflammation, and Angiogenesis.,  60  (9): [PMID:28445047] [10.1021/acs.jmedchem.6b01703]

Source

Source(1):

• Scientific Literature